EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access

Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598

Kenan Gu iD, Robert Spitz, Erin Hammett, Anna Jaunarajs, Varduhi Ghazaryan, Edward P Garvey, Thorsten Degenhardt

Medical Mycology · 2024

DOI: 10.1093/mmy/myae032 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Medical Mycology, 2024. Verfasst von Kenan Gu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health…. Hauptthemen laut MEDLINE: Antifungal Agents, Tetrazoles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

VT-1598 is a novel fungal CYP51 inhibitor and 1-tetrazole-based antifungal drug candidate with improved selectivity minimizing off-target binding to and inhibition of human CYP450 enzymes. Data are presented from this first clinical study in the evaluation of the safety and pharmacokinetic (PK) of single ascending doses of 40, 80, 160, 320, and 640 mg VT-1598, comprising a 160 mg cohort in both fasting and fed states. Eight healthy adults per dose were randomized to receive either oral VT-1598 or placebo (3:1). Over the dose range, exposures were with relatively high variation. The maximum plasma concentrations (Cmax) for VT-1598 were 31.00–279.4 ng/ml and for its primary metabolite, VT-11134, were 27.80–108.8 ng/ml. The plasma area under the concentration–time curve to the last measurable concentration (AUC0–last) for VT-1598 were 116.1–4507 ng*h/ml, and for VT-11134 were 1140–7156 ng*h/ml. The dose proportionality was inconclusive based on the results of the power model. The peak concentration time (Tmax) was 4–5 h for VT-1598 and for VT-11134. Half-life was 103–126 h for VT-11134. After food intake, Cmax of VT-1598 increased by 44% (geometric mean ratio (GMR), 1.44; 90%CI [0.691, 2.19]) and AUC0–last by 126% (GMR, 2.26; 90%CI [1.09, 3.44]), while exposure of VT-11134 was decreased 23% for Cmax (GMR, 0.77; 90%CI [0.239, 1.31]) and unchanged for AUC0–last (GMR, 1.02; 90%CI [0.701, 1.33]). Neither VT-1598 nor VT-11134 were detected in urine. No serious adverse events (AEs) or AEs leading to early termination were observed. The safety and PK profiles of VT-1598 support its further clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsTetrazolesHumansAdultDouble-Blind MethodMaleAdministration, OralHealthy VolunteersYoung AdultFemaleMiddle AgedPlacebosArea Under CurvePlasma

Stichwörter der Autor:innen

VT-1598first-in-human studyoral dosesafety and pharmacokineticstetrazole antifungal

Substanzen

Antifungal AgentsTetrazolesPlacebos

Autor:innen und Institutionen

  • Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
  • Medical & Scientific Affairs, ICON plc, Blue Bell, PA 19422, USA.
  • Department of Biometrics & Clinical Operations, The Emmes Company, Rockville, MD 20850, USA.
  • Department of Research and Development, Mycovia Pharmaceuticals, Durham, NC, 27709, USA.

ORCID-Profile: Kenan Gu

Förderung

  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Gu, K., Spitz, R., Hammett, E., Jaunarajs, A., Ghazaryan, V., Garvey, E. P., & Degenhardt, T. (2024). Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598. Medical Mycology. https://doi.org/10.1093/mmy/myae032

Vancouver

Gu K, Spitz R, Hammett E, Jaunarajs A, Ghazaryan V, Garvey EP, et al. Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598. Medical Mycology. 2024. doi:10.1093/mmy/myae032

BibTeX
@article{Gu2024,
  author = {Gu, Kenan and Spitz, Robert and Hammett, Erin and Jaunarajs, Anna and Ghazaryan, Varduhi and Garvey, Edward P and Degenhardt, Thorsten},
  title = {Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598},
  journal = {Medical Mycology},
  year = {2024},
  doi = {10.1093/mmy/myae032}
}
Kostenlos starten →